A novel platform that addresses the root cause of autoimmune disease, treating these chronic diseases in a fundamentally new way. Currently in advanced clinical development with our first therapy, the Tolerion platform addresses autoimmune diseases directly at the root level by teaching the immune system to tolerate the specific antigen causing the autoimmune response. The elegance of the Tolerion approach is we can do this without suppressing the immune system more broadly.
Our three named clinical candidate programs to treat autoimmune disorders in which the disease-causing self-antigen is identified include: type-1 diabetes, myasthenia gravis and neuromyelitis optica. Second generation application of our platform is focused on teaching specific tolerance to proteins presented in gene therapy solutions where immunogenicity is often problematic. We have multiple preclinical programs in this area.
TOL-3021, our lead product, is a tolerizing biologic in late-stage clinical development with potential to be the first disease-modifying therapy for patients with type 1 diabetes.